Wolfgang Link, Salvatore Princiotto, Lucía Jiménez, Lucía Domínguez, João G N Sequeira, Cristiana Mourato, Alba Orea-Soufi, Bruno Santos, Sabrina Dallavalle, Miguel Machuqueiro, Bibiana I Ferreira
{"title":"染色质衍生物作为靶向胶质母细胞瘤的CRM1抑制剂。","authors":"Wolfgang Link, Salvatore Princiotto, Lucía Jiménez, Lucía Domínguez, João G N Sequeira, Cristiana Mourato, Alba Orea-Soufi, Bruno Santos, Sabrina Dallavalle, Miguel Machuqueiro, Bibiana I Ferreira","doi":"10.1002/cbic.202500195","DOIUrl":null,"url":null,"abstract":"<p><p>Glioblastoma (GBM) is one of the most aggressive and deadly cancers. Due to the complexity and redundancy within signaling networks in GBM, targeted inhibitors of specific pathways have shown only limited success. The nuclear export receptor Chromosome Region Maintenance 1 (CRM1) has recently emerged as a promising therapeutic target, as its inhibition can simultaneously disrupt multiple key oncogenic drivers. In this study, we explore whether chromenone derivatives, known for detecting thiol-containing molecules, can function as CRM1 inhibitors. We synthesized several chromenone-based derivatives and demonstrated that they inhibit CRM1-driven nuclear export in a structure- and dose-dependent manner. A preliminary structure-activity relationship (SAR) was established, providing a rationale for selective CRM1 binding based on molecular docking studies. Additionally, we showed that the active chromenone derivatives effectively inhibit the nuclear export of endogenous nuclear export signal (NES)-containing substrates in glioblastoma cells. Several of these compounds exhibit selective cytotoxicity against glioblastoma cell lines, highlighting their potential as targeted therapies for GBM.</p>","PeriodicalId":140,"journal":{"name":"ChemBioChem","volume":" ","pages":"e202500195"},"PeriodicalIF":2.6000,"publicationDate":"2025-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Chromenone derivatives as CRM1 Inhibitors for Targeting Glioblastoma.\",\"authors\":\"Wolfgang Link, Salvatore Princiotto, Lucía Jiménez, Lucía Domínguez, João G N Sequeira, Cristiana Mourato, Alba Orea-Soufi, Bruno Santos, Sabrina Dallavalle, Miguel Machuqueiro, Bibiana I Ferreira\",\"doi\":\"10.1002/cbic.202500195\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glioblastoma (GBM) is one of the most aggressive and deadly cancers. Due to the complexity and redundancy within signaling networks in GBM, targeted inhibitors of specific pathways have shown only limited success. The nuclear export receptor Chromosome Region Maintenance 1 (CRM1) has recently emerged as a promising therapeutic target, as its inhibition can simultaneously disrupt multiple key oncogenic drivers. In this study, we explore whether chromenone derivatives, known for detecting thiol-containing molecules, can function as CRM1 inhibitors. We synthesized several chromenone-based derivatives and demonstrated that they inhibit CRM1-driven nuclear export in a structure- and dose-dependent manner. A preliminary structure-activity relationship (SAR) was established, providing a rationale for selective CRM1 binding based on molecular docking studies. Additionally, we showed that the active chromenone derivatives effectively inhibit the nuclear export of endogenous nuclear export signal (NES)-containing substrates in glioblastoma cells. Several of these compounds exhibit selective cytotoxicity against glioblastoma cell lines, highlighting their potential as targeted therapies for GBM.</p>\",\"PeriodicalId\":140,\"journal\":{\"name\":\"ChemBioChem\",\"volume\":\" \",\"pages\":\"e202500195\"},\"PeriodicalIF\":2.6000,\"publicationDate\":\"2025-04-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemBioChem\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://doi.org/10.1002/cbic.202500195\",\"RegionNum\":4,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemBioChem","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1002/cbic.202500195","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
Chromenone derivatives as CRM1 Inhibitors for Targeting Glioblastoma.
Glioblastoma (GBM) is one of the most aggressive and deadly cancers. Due to the complexity and redundancy within signaling networks in GBM, targeted inhibitors of specific pathways have shown only limited success. The nuclear export receptor Chromosome Region Maintenance 1 (CRM1) has recently emerged as a promising therapeutic target, as its inhibition can simultaneously disrupt multiple key oncogenic drivers. In this study, we explore whether chromenone derivatives, known for detecting thiol-containing molecules, can function as CRM1 inhibitors. We synthesized several chromenone-based derivatives and demonstrated that they inhibit CRM1-driven nuclear export in a structure- and dose-dependent manner. A preliminary structure-activity relationship (SAR) was established, providing a rationale for selective CRM1 binding based on molecular docking studies. Additionally, we showed that the active chromenone derivatives effectively inhibit the nuclear export of endogenous nuclear export signal (NES)-containing substrates in glioblastoma cells. Several of these compounds exhibit selective cytotoxicity against glioblastoma cell lines, highlighting their potential as targeted therapies for GBM.
期刊介绍:
ChemBioChem (Impact Factor 2018: 2.641) publishes important breakthroughs across all areas at the interface of chemistry and biology, including the fields of chemical biology, bioorganic chemistry, bioinorganic chemistry, synthetic biology, biocatalysis, bionanotechnology, and biomaterials. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies, and supported by the Asian Chemical Editorial Society (ACES).